How Market Leaders Are Shaping the Future of Remote Diabetes Monitoring

A Market Reshaping for Tomorrow's Industry

We observed that the Remote Diabetes Monitoring market is going through a major change. New technology is pushing old methods to the side. Our analysis shows a clear shift toward smart, reliable systems built for today's care needs.

This market is set to grow fast. It will rise from USD 9.6 Billion in 2025 to an impressive USD 31.4 Billion by 2035. That is a strong 12.6% compound annual growth rate (CAGR) from 2026 to 2035.

The market's growth is clear across its main segments:

Source: Healthcare Industry Insights Analysis, 2026

Market share still depends on who controls the best technology. Big names keep strong revenue. Smaller, fast growing areas are pulling in new money and research spending.

Medtronic plc

Medtronic plc is one of the biggest names in diabetes care. Its diabetes business now runs as MiniMed, a focused unit built to move faster. The company combines insulin pumps with glucose sensors in one connected setup.

Medtronic is also pushing into automated insulin delivery. These systems adjust insulin on their own using sensor data. This helps patients stay in range even between clinic visits. Its global hospital and clinic ties give it a big head start.

Sources: medtronic.com (newsroom, 2025/2026).

Medtronic's strategy fits three big market shifts. Automation, digital health, and steady supply chains are now must haves. Its focus on connected devices puts it right in the middle of these trends.

Its focus on smart delivery systems also helps with supply planning. Buyers want partners they can count on. Medtronic's size makes that promise easier to keep.

For stakeholders, the value is clear. Hospitals and payers gain systems that cut hospital visits. Patients gain tools that reduce daily guesswork. This creates steady demand through the forecast period.

Abbott Laboratories

Abbott Laboratories is a giant in glucose monitoring. Its FreeStyle Libre line has reached many people around the world. The company is known for easy to use sensors that do not need finger pricks.

Abbott has invested heavily in making its sensors smaller and more accurate. It also builds apps that show trends in simple charts. These tools help both patients and care teams make quick choices.

Sources: abbott.com (investor relations, 2026).

Abbott's manufacturing scale is one of its biggest strengths. It can produce sensors in large volumes across many sites. That helps it meet demand in both rich and developing markets.

Its investment in new plants and digital tools supports long term growth. Each new sensor version opens fresh markets. Abbott is well placed to win share as remote care spreads.

Abbott's reach across North America, Europe, and Asia Pacific gives it a wide base. Asia Pacific is expected to grow quickly, and Abbott is positioned to benefit. Its presence in many regions makes it hard to match.

Dexcom, Inc.

Dexcom, Inc. is a leader in real time continuous glucose monitoring. Its sensors send readings to phones and receivers without manual scans. The company built its name on accuracy and ease of use.

Dexcom has expanded its platform with new sensor generations. These updates aim to last longer and need fewer fingerstick checks. The company also works to connect its data with insulin pumps and other devices.

Sources: dexcom.com (newsroom, 2025/2026).

Dexcom's focus on data sharing matches the move toward connected care. Care teams can review patient data between visits. This supports faster treatment changes and better follow up.

Dexcom is also building partnerships with digital health and pharmacy groups. These links help it reach patients beyond traditional clinics. Its brand trust gives it an edge in new settings.

Its advantage lies in the depth of its data and software. Each new user adds to a growing data set. That makes its platform more useful and harder for rivals to copy.

Dexcom's growth creates value for insurers and health systems too. Remote monitoring can lower the cost of complications. Over the forecast period, this value case should keep demand strong.

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. focuses on advanced insulin pump systems. Its t:slim X2 pump is known for a slim touch screen design. The company also offers automated features that adjust insulin dosing.

Tandem has worked to connect its pumps with CGM sensors from other brands. This open approach gives patients more choice. It also makes the platform easier to fit into existing care plans.

Sources: tandemdiabetes.com (newsroom, 2025/2026).

Tandem's strategy follows the rise of automated care and digital tools. Its software updates can add features without new hardware. This keeps devices useful for longer periods.

The company also supports clinics with training and remote data review. These services help busy teams manage more patients. That makes Tandem a valued partner, not just a device seller.

For stakeholders, Tandem offers strong value in automated insulin delivery. Patients get better control with less daily effort. Its focus on user experience helps it compete for long term loyalty.

Insulet Corporation

Insulet Corporation is known for its tubeless insulin delivery system. The Omnipod platform uses a small pod that sticks to the skin. Many users like that it removes the need for tubing.

Insulet has pushed to make its pods easier to use and more automated. It has also worked to expand access through insurance and pharmacy channels. These steps help more people try the system.

Sources: insulet.com (newsroom, 2026).

Insulet's model fits the shift toward simple, wearable care. Its tubeless design appeals to people who want more freedom. The company's focus on ease of use matches the broader move toward home based treatment.

Its pods link to smart apps that track insulin and glucose trends. This creates a steady flow of data for care teams. It also builds a habit of regular use, which drives repeat revenue.

Insulet is a critical technology enabler for the wider remote monitoring ecosystem. Its platform works with sensors and apps from other companies. That role gives it influence across many commercial markets.